Other large players in the oncology space are AstraZeneca (AZN) , Merck (MRK) and Bristol-Myers (BMY) For AstraZeneca, oncology sales now comprise around 41% of total revenues. Sales in its oncology segment rose 13% in the first quarter of 2025. AstraZeneca's strong oncology performance was driven by medicines such as Tagrisso, Lynparza, Imfinzi, Calquence and Enhertu (in partnership with Daiichi Sankyo). Key Takeaways Pfizer (PFE) has committed significant resources for the development of treatments in the ...

J&J’s (JNJ) stock has declined 6.4% in the past three months. J&J faces several challenges, including slowing sales in the MedTech segment, loss of exclusivity of its blockbuster drug, Stelara, and uncertainty around the talc lawsuits, among others.In addition to that, broader market uncertainties and a volatile macroeconomic environment continue to hurt the stock.The sky-high tariffs imposed by the United States and retaliatory tariffs by China and some other countries have been affecting global stock mark ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) RBC Capital Markets Global Healthcare Conference May 20, 2025 11:00 AM ET Company Participants Mark Hudson - Senior Director of Investor Relations George D. Yancopoulos - Board Co-Chair, President and Chief Scientific Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Brian Abrahams Our next featured company, Regeneron, has always been known for its R&D engine. And, there’s a lot more coming from their pipeline, really over the next 6 mont ...

Jazz Pharmaceuticals (JAZZ) Q1 2025 Earnings Call May 06, 2025 04:30 PM ET Company Participants Jeff Macdonald - Executive director & IRBruce Cozadd - Chairman and Chief Executive OfficerRenée Galá - President & COORobert Iannone - Executive VP, Chief Medical Officer and Global Head of Research & DevelopmentPhilip Johnson - Executive VP & CFOJason Gerberry - MD & Equity ResearchMarc Goodman - Senior MD - NeuroscienceAnnabel Samimy - Managing DirectorAmy Li - SVP Equity ResearchAshwani Verma - Executive Dire ...